Pricing Log in Create free account

ImmuCell Corporation (ICCC) vs Immunic, Inc. (IMUX)

ImmuCell Corporation and Immunic, Inc. are both Biotechnology companies. ImmuCell Corporation and Immunic, Inc. are of similar size ($96.9M and $95.9M). Immunic, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 126×. ImmuCell Corporation has the higher net margin (2.57% vs 0.00%) and the higher return on invested capital (7.84% vs 0.00%). Across the 14 metrics below, ImmuCell Corporation leads on 10 and Immunic, Inc. on 4.

Valuation

Metric ICCC IMUX Biotechnology median
P/E 126.00 n/m 8.50
P/S 3.15 n/m 9.71
P/B 3.08 2.32 2.13
Price to free cash flow 22.84 n/m 20.82
EV/EBITDA 15.27 n/m 0.64
EV/Sales 3.13 n/m 9.21
Earnings yield 0.79% (62.84%) (33.15%)
Free cash flow yield 4.38% (29.71%) (25.50%)

Profitability

Metric ICCC IMUX Biotechnology median
Gross margin 40.32% 0.00% 65.16%
Operating margin 12.60% 0.00% 0.00%
Net margin 2.57% 0.00% 0.00%
Free cash flow margin 13.79% 0.00% 0.00%
Return on equity 2.57% (138.17%) (56.36%)
Return on assets 1.69% (101.15%) (48.04%)
Return on invested capital 7.84% 0.00% 0.00%

Growth

Metric ICCC IMUX Biotechnology median
Revenue growth (TTM) 8.49% — 6.02%
EPS growth (last fiscal year) 53.85% 38.00% 30.26%
Revenue growth, 5-year CAGR 12.50% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ICCC IMUX Biotechnology median
Debt to equity 0.26 0.00 0.00
Current ratio 4.75 5.05 4.72
Net debt to EBITDA 1.19 0.15 0.96

Dividend

Metric ICCC IMUX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ICCC IMUX Biotechnology median
Market cap 95.90m 96.87m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack